p14ARF promoter methylation and its clinical correlation in primary liver cancer in the population of North China

Zhang JunXia; Wang Yan; Zhao YanPing; Zhang Bei; Li Jia; Huang Jian

Issue 10

Oct. 2011

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2011 > 27(10): 1051-1054

PDF( 1236 KB)

p14ARF promoter methylation and its clinical correlation in primary liver cancer in the population of North China

Research funding:

Published Date: 2011-10-20

Abstract

Abstract

Objective To explore the clinical correlation between p14ARF promoter methylation and primary liver cancer through analysis of p14ARF promoter methylation in primary liver cancer in the population of North China.Methods By the method of methylation specific PCR (MSP) , the detection of p14ARF promoter methylation in 111 cases of primary liver cancer and 22 cases of adjacent non-tumor tissue were carried out, and then correlated with different clinical variables, such as tumor type, tumor stages, differentiation of tumor cell and with or without HBV infection in tumor.Results Significant difference (P=0.010) of p14ARF promoter methylation between hepatocellular carcinomas (HCC) and adjacent non-tumor tissue was found, with the ratio of 33.7% (29/86) in primary liver cancer and 5.0% (1/20) in non-tumor tissue.Higher frequency of p14ARF promoter methylation was identified in HCC with tumor stage of TNM1 compared with tumor stage of more than TNM1 (P=0.027) .No correlation was found between p14ARF promoter methylation and differentiation of tumor cell and with or without HBV infection in HCC, as well as between p14ARF promoter methylation and tumor stages, differentiation of tumor cell and with or without HBV infection in intrahepatic cholangiocellular carcinoma (ICC) .Conclusion p14ARF promoter methylation may constitute one of the important mechanism in inactivation of p14ARF gene and maybe involved in the development and progression of HCC.
- carcinoma,
- hepatocellular,
- tumor suppressor protein p14ARF

FullText(HTML)

References(10)

References

[1]ZenderL, Spector MS, Xue W, et al.Identification and vali-dation of oncogenes in liver cancer using an integrative on-cogenomic approch[J].Cell, 2006, 125:1253-1267.

[2]陈军, 阳春, 吴飞翔, 等.肝细胞癌中p14ARF基因启动子甲基化及蛋白表达的研究[J].病理诊断学杂志, 2008, 15 (3) :202-205.

[3]Huang J, Grotzer MA, Watanabe T, et al.Mutations in theNijmegen breakage syndrome gene in medulloblastomas[J].Clin Cancer Res, 2008, 14 (13) :4053-4058.

[4]Pimkina IuS, Dorosevich AE.Role of the tumor suppressorARF in oncogenesis[J].Arkh Patol, 2009, 71:60-63.

[5]Esteller M, Tortola S, Toyota M, et al.Hypermet hylationassociated inactivation of p14 (ARF) is independent of p16 (INK4a) met hylation and p53 mutational status[J].CancerRes, 2000, 60 (1) :129-133.

[6]Weihrauch M, Markwart h A, Lehnert G, et al.Abnormali-ties of the ARF-p53 pathway in primary angiosarcomas of the liver[J].Hum Pat hol, 2002, 33 (9) :884-892.

[7]Xing EP, Nie Y, Song Y, et al.Mechannisms of inactivationof p14ARF, P15INK4b, and P16INK4αgene in human esopha-geal squamous cell carcinoma[J].Clin Cancer Res, 1999, 5 (10) :2704-2713.

[8]左超海, 高炎明.p14ARF与人类肿瘤[J].海南医学院学报, 2005, 11 (1) :78-80.

[9]Kawamoto K, Emokida H, Gotanda T, et al.P16INK4a andp14ARF methylation as a potential biomarker for human blad-der cancer[J].Biochem Biophys Res Commun, 2006, 339 (3) :790-796.

[10]肖开银.原发性肝癌流行病学研究进展[J].中国普外基础与临床杂志, 2000, 7 (4) :272-274.)

Relative Articles

[1]	Hou YiHui, Liu TengFei, Zhao XiaoQing, Zhang LiaoYun. Effect of different direct-acting antivirals on the clinical outcome of genotype 1b chronic hepatitis C and compensated hepatitis C cirrhosis[J]. Journal of Clinical Hepatology, 2020, 36(1): 84-87. doi: 10.3969/j.issn.1001-5256.2020.01.019
[2]	Zhang JieBing, Guo HongHua. Research advances in hepatitis B cirrhosis with renal injury and the application of antiviral drugs[J]. Journal of Clinical Hepatology, 2019, 35(1): 191-196. doi: 10.3969/j.issn.1001-5256.2019.01.042
[3]	Zhang Xi, Li YongGuo. Current status of the application of direct-acting antiviral agents in treatment of chronic hepatitis C and existing problems[J]. Journal of Clinical Hepatology, 2018, 34(4): 853-857. doi: 10.3969/j.issn.1001-5256.2018.04.034
[4]	Ren Shan, Chen XinYue. Current research on hepatitis C virus resistance to direct-acting antiviral agents[J]. Journal of Clinical Hepatology, 2015, 31(11): 1807-1812. doi: 10.3969/j.issn.1001-5256.2015.11.010
[5]	Yang YanLin, Xiao Ping, Gao Peng, Wang LiMing, Wei XiSheng, He Qiang, Zhou Ping. Distribution of HBV genotypes and YMDD mutations in E antigen-positive patients[J]. Journal of Clinical Hepatology, 2012, 28(6): 428-430.
[6]	Zhang YanMei, Ding XiaoHui. Anti-viral therapy in adult patients with acute hepatitis B[J]. Journal of Clinical Hepatology, 2011, 27(12): 1327-1330+1344.
[7]	Guo XinHui, Yan Yan, Li Zhuo, Yin JiMing. Fluorescent reverse transcription-PCR assay for determination of hepatitis C virus genotypes[J]. Journal of Clinical Hepatology, 2011, 27(1): 65-67.
[8]	Cheng Ling, Hong GuoHu, Guo Yan, Mao Qing. Prediction of HLA-DRB1*0311/0401 in recognizing epitopes of HCV Core protein of different genotypes[J]. Journal of Clinical Hepatology, 2011, 27(1): 61-64.
[9]	Liu JinPing, Liu YouDe, Guo YanMei, Yang ShaoPing, Lin Qing, Lin Ling. Clinical characteristics and distribution of hepatitis B virus genotypes in CHB patients in Yantai area[J]. Journal of Clinical Hepatology, 2011, 27(12): 1288-1290.
[10]	Qin Hua, Wu XiaoQing. Distribution and clinical significance of HBV genotypes in Lanzhou district[J]. Journal of Clinical Hepatology, 2010, 26(3): 295-296.
[11]	Zhang WenJie, Liu LiJun, Du ShaoCai, Li ChaoXia, Lu QingYun, Yang ShaoHua. The prevalence of hepatitis C virus genotype in Lanzhou area[J]. Journal of Clinical Hepatology, 2010, 26(3): 290-291+294.
[12]	Wang GuoQiang, Niu JuXia. The HBx protein mutation among different HBV genotypes[J]. Journal of Clinical Hepatology, 2010, 26(4): 392-394.
[13]	Chen Yan, Tian DeYing, Xia NingShao. Epidemiology and the genotypes of HEV isolated from patients with hepatitis E in Wuhan[J]. Journal of Clinical Hepatology, 2006, 22(1): 36-38.
[14]	Xiao Yang, Hu CaoHan, Zhou YueJin, Xie QingRong, Zhu BingXing, Hu Xia, Wang KaiJian, Zhang WenJing. Effect of hepatitis B virus genotypes on response to interferon α2b in the treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2006, 22(2): 105-106.
[15]	Liu ChengYong, Hou YuanPei, Qian XiuMei, Sun Qing, Song Li. Distribution of hepatitis B virus genotype in Xuzhou and its clinical significance[J]. Journal of Clinical Hepatology, 2005, 21(3): 151-152.
[16]	Li TingMing, Zhu YouFu, He HaiTang, Mao QianGuo, Wu AiHua, Liang YuFang, Luo KangXian. The relation between chinese hepatitis B virus genotype B C and efficacy of interferon-α.[J]. Journal of Clinical Hepatology, 2005, 21(1): 16-18.
[18]	Xu ZhengJu, Yang Hong, Zhang QiHua, Chen XianLi, Li ShuQing, Wang ChongGuo. Study on the relationship between hepatitis B virus genotypes and effect of lamivudine therapy.[J]. Journal of Clinical Hepatology, 2005, 21(3): 157-159.
[19]	Jiao Jian, Wang JiangBin. Distribution of HCV genotypes and its clinical features in patients coinfected with HCV and HBV[J]. Journal of Clinical Hepatology, 2004, 20(2): 75-76.
[20]	Yao Gang, Zhang Lian, Bao LiHua. HBV genotypes and efficacy of interferon-α on patients with chronic hepatitis B.[J]. Journal of Clinical Hepatology, 2002, 18(5): 273-274.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2869) PDF downloads(704)

p14ARF promoter methylation and its clinical correlation in primary liver cancer in the population of North China

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

p14ARF promoter methylation and its clinical correlation in primary liver cancer in the population of North China

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content